§ Federal grant opportunity · RFA-NS-26-034
Functional Target Validation for Alzheimer's Disease-Related Dementias
National Institutes of Health is accepting applications for Functional Target Validation for Alzheimer's Disease-Related Dementias. The deadline is Rolling / not published and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- Rolling / not published
- Award range
- Award amount not published
- Eligibility
- other native american tribal organizations, state governments, independent school districts, city or township governments, other, nonprofits non higher education without 501c3, public and state institutions of higher education, nonprofits non higher education with 501c3, federally recognized native american tribal governments, private institutions of higher education, small businesses, public and indian housing authorities, county governments, special district governments, for profit organizations other than small businesses
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- RFA-NS-26-034
Program overview
The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting ambitious research projects that propose comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease–Related Dementias (ADRD). A major barrier to the development of effective treatments for ADRD, as well as other complex central nervous system disorders, is the lack of well-validated targets that are clearly linked to disease mechanisms. Successful translation of basic discoveries into the clinic depends on the rigor of target validation and confidence in a causal relationship between modulation of a target and its functional physiological consequences relevant to treating or preventing disease. This initiative aims to de-risk subsequent translational research and accelerate the development of novel therapeutic strategies. NINDS believes that this initiative would be most appropriately supported by a phased award mechanism (for example, R61/R33). In the initial phase, support would be provided for the development of customized technologies, models, and protocols to modulate the expression or activity of candidate targets and to assess their physiological consequences in relevant in vitro and in vivo disease models. Upon successful achievement of predefined, milestone-based technical feasibility and proof-of-concept criteria, projects would transition to the second phase focused on measuring and cross-validating the effects of target modulation across multiple experimental modalities and collaborating laboratories, in accordance with NIH rigor and reproducibility guidelines. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop responsive projects and establish appropriate cross-disciplinary collaborations.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before Rolling / not published, allowing time for registration and validation.
Related grant opportunities
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.